At a glance
- Originator AstraZeneca
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease; Schizophrenia
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 05 Feb 1997 Preclinical development for Schizophrenia in Sweden (Unknown route)
- 06 Apr 1995 Preclinical development for Parkinson's disease in Sweden (Unknown route)